Effect of 1,25-dihydroxyvitamin D3 on plasma prolactin in patients with renal failure on regular dialysis treatment

1983 ◽  
Vol 6 (5) ◽  
pp. 359-362 ◽  
Author(s):  
D. Verbeelen ◽  
L. Vanhaelst ◽  
A. C. Van Steirteghem ◽  
J. Sennesael
Keyword(s):  
Renal Failure ◽  
Plasma Prolactin ◽  
Dihydroxyvitamin D3 ◽  
Dialysis Treatment ◽  
1,25 Dihydroxyvitamin D3 ◽  
Regular Dialysis Treatment

Effects of I ,25-Dihydroxyvitamin-D3 on Renal Function, Mineral Balance, and Growth in Children with Severe Chronic Renal Failure

PEDIATRICS ◽  
1981 ◽  
Vol 68 (4) ◽  
pp. 559-571
Author(s):  
James C. M. Chan ◽  
Michael B. Kodroff ◽  
Douglas M. Landwehr
Keyword(s):  
Renal Failure ◽  
Renal Function ◽  
Glomerular Filtration Rate ◽  
Renal Insufficiency ◽  
Filtration Rate ◽  
Height Velocity ◽  
Dihydroxyvitamin D3 ◽  
Mineral Balance ◽  
1,25 Dihydroxyvitamin D3 ◽  
Calcium Phosphorus

To confirm and extend previous observations of enhanced linear growth in children with chronic renal disease being treated with 1,25-dihydroxyvitamin- D3 and to characterize further the calcium, phosphorus, magnesium, and zinc disorders in renal failure, 11 children (mean age 8 ± 5 years) with chronic renal insufficiency (glomerular filtration rate 18% ± 13% of normal) were evaluated on the basis of their reciprocal serum creatinine concentrations, height-velocity curves, mineral balances, and radiologic findings. Reciprocal serum creatinine concentrations analyzed retrospectively and prospectively during 32 months of 1,25-dihydroxyvitamin-D3 therapy showed progression of renal failure at rates linearly identical with those before treatment, thus suggesting that the treatment did not accelerate the rate of deterioration of glomerular filtration rate in chronic renal insufficiency. Indeed, one patient manifested a lesser decline in renal function (P sjlt .05). The height velocity of six of the children (75%) less than 12 years of age improved markedly over that expected for chronologic and bone ages after one year of treatment with orally administered 1,25-dihydroxyvitamin-D3, 15 to 35 ng/kg/day. All other medications except vitamin D2 were continued at their pretreatment dosage levels throughout the study. Growth velocity was unimproved in two of three children older than 12 years at the initiation of 1,25-dihydroxyvitamin- D3 therapy. Mineral balance data showed significant retention of calcium, phosphorus, magnesium, and zinc (357 ± 32 mg/sq m/day, 250 ± 82 mg/sq m/day, 38 ± 32 mg/sq m/day, and 1,157 ± 283 µ/sq m/day, respectively), after treatment for 12 months. In addition, serum calcium, alkaline phosphatase, and parathyroid hormone concentrations returned toward normal. Finally, healing of renal osteodystrophy was radiologically evident after six months of therapy.

scholarly journals Clinical aspects of chronic renal failure at the initiation of regular dialysis treatment

1988 ◽  
Vol 21 (7) ◽  
pp. 613-619
Author(s):  
Akira Oya ◽  
Shigeru Miyagata ◽  
Ryuuzou Kato ◽  
Tadashi Harada ◽  
Seigi Tsuchida
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Clinical Aspects ◽  
Dialysis Treatment ◽  
Regular Dialysis Treatment

scholarly journals Clinical aspects of diabetic end-stage renal failure at the initiation of regular dialysis treatment

1985 ◽  
Vol 18 (4) ◽  
pp. 385-391
Author(s):  
Hideki Hirakata ◽  
Masahiko Nakamoto ◽  
Setsuko Shimoyama ◽  
Mayumi Konomi ◽  
Satoru Fujimi
Keyword(s):  
Renal Failure ◽  
Clinical Aspects ◽  
Dialysis Treatment ◽  
End Stage Renal Failure ◽  
Regular Dialysis Treatment ◽  
End Stage

Iron Metabolism in Patients with Chronic Renal Failure on Regular Dialysis Treatment

1971 ◽  
Vol 41 (4) ◽  
pp. 345-351 ◽  
Author(s):  
D. H. Lawson ◽  
K. Boddy ◽  
P. C. King ◽  
A. L. Linton ◽  
G. Will
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Iron Metabolism ◽  
Oral Absorption ◽  
The Body ◽  
Whole Body ◽  
Dialysis Treatment ◽  
Regular Dialysis Treatment ◽  
Considerable Controversy

1. By using a whole-body monitoring technique iron metabolism has been investigated in patients suffering from chronic renal failure who required regular dialysis treatment. 2. Oral absorption of inorganic iron was low. 3. The incorporation of radioactive iron into erythrocytes was diminished. 4. The rate of loss of radioactive iron from the body was significantly greater than in normal control and non-dialysed patients with chronic renal failure. 5. Iron exchange between dialysate and patient was studied. Patients with chronic renal failure are known to have a decreased rate of erythropoiesis and to develop abnormalities in iron metabolism (Kaye, 1958; Logue, Lange & Moore, 1958; Boddy, Lawson, Linton & Will, 1970). However, considerable controversy exists about the effect of haemodialysis on iron metabolism in such patients (Shaldon, 1966; Eschbach, Funk, Adamson, Kuhn, Scribner & Finch, 1967; Eschbach, Cook & Finch, 1970). The use of a whole-body monitor permitted measurement in a single study of the oral absorption of a tracer dose of 59Fe, its incorporation into erythrocytes and the subsequent long-term rate of loss of 59Fe from the body. We have previously reported the results of an investigation of iron metabolism by using this method in patients with chronic renal failure (Boddy et al., 1970). We now report the results of a similar investigation of iron metabolism in patients with chronic renal failure undergoing regular haemodialysis therapy.

scholarly journals The Effect of 1,25 Dihydroxyvitamin D3 on Lymphocyte Transformation in Patients with Chronic Renal Failure.

1995 ◽  
Vol 34 (4) ◽  
pp. 240-242 ◽  
Author(s):  
Önder ALPDOGAN ◽  
Sukran ÖZGUN ◽  
Roger LAWRENCE ◽  
Cetin ÖZENER ◽  
Emel AKOGLU ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Lymphocyte Transformation ◽  
Dihydroxyvitamin D3 ◽  
1,25 Dihydroxyvitamin D3
Sign in / Sign up

Export Citation Format

Share Document